Elevated pre-eclampsia risk in lupus nephritis and antiphospholipid syndrome: a nationwide Spanish registry analysis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40971681.
- Also identified by DOI 10.1093/rheumatology/keaf484 and PMC identifier 12862370.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Evaluate the association of APS and SLE, focusing on LN, with risk of pre-eclampsia (PE) and PE with severity criteria (PESC). Analysis of pregnant women admitted between 2016-2022, using data from the Spanish Hospital Discharge Database. Factors associated with PE and PESC, including early-onset PE, severe PE, eclampsia and HELLP syndrome were evaluated. Among 1 973 249 admissions, 1787 patients had SLE (9.1‰), with prior LN in 13.2%. SLE patients experienced higher PE (5.5% vs 2.1%) and PESC (2.1% vs 0.6%) rates; these rose further in SLE women with LN alone (PE: 10.3%, PESC: 4.2%) or with both LN and APS (PE: 22.7%, PESC: 9.1%) . Adjusted analyses showed PE and PESC were each associated with SLE (OR = 1.78, 95% CI 1.39-2.28; OR = 2.17, 95% CI 1.47-3.22), LN (OR = 1.94, 95% CI 1.18-3.19; OR = 2.45, 95% CI 1.18-5.09) and APS (OR = 1.53, 95% CI 1.28-1.84; OR = 1.91, 95% CI 1.44-2.54). Within SLE patients, baseline hypertension (OR = 4.27, 95% CI 2.45-7.44), LN (OR = 2.06, 95% CI 1.26-3.37) and APS (OR = 1.85, 95% CI 1.03-3.32) were linked to PE, while LN alone predicted PESC (OR = 2.88, 95% CI 1.41-5.91). The risk of PE and PESC that patients with SLE exhibit is further amplified in those with a history of LN or APS. Recognizing SLE, APS and especially LN is crucial for precise risk stratification and tailored management to improve maternal and fetal outcomes.
Medical subject headings
- Pre-Eclampsia
- Lupus Nephritis
- Antiphospholipid Syndrome